tDCS for Huntington's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment called transcranial direct current stimulation (tDCS) for individuals with Huntington's disease (HD). The researchers aim to determine if tDCS can improve behavior, thinking, and other symptoms in the early to middle stages of HD. Individuals with a confirmed HD diagnosis and mild to moderate symptoms, such as anxiety or depression, might be suitable candidates. The study will also assess the treatment's safety and acceptability. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could lead to new treatment options for HD.
Will I have to stop taking my current medications?
The trial requires that participants have stable doses of their medications for at least one month, so you will not need to stop taking your current medications if they are stable.
What prior data suggests that transcranial direct current stimulation (tDCS) is safe for Huntington's Disease patients?
Research has shown that transcranial direct current stimulation (tDCS) is generally safe for people with Huntington's Disease. One study applied tDCS to the cerebellum and reported no major safety issues, suggesting the treatment's safety. Another study found that tDCS on the dorsolateral prefrontal area was well-tolerated and improved working memory compared to a placebo. These findings support the idea that tDCS is a safe option for people with Huntington's.12345
Why are researchers excited about this trial?
Researchers are excited about active transcranial direct current stimulation (tDCS) for Huntington's Disease because it offers a non-invasive and potentially safer alternative to current treatments. Unlike traditional options that mainly include medication to manage symptoms and do not alter disease progression, tDCS uses a mild electrical current to stimulate specific areas of the brain. This unique approach aims to improve motor and cognitive functions directly by modulating brain activity, which could lead to better outcomes with fewer side effects. The potential for tDCS to enhance quality of life without the risks associated with pharmaceuticals is what makes it particularly promising.
What evidence suggests that tDCS is effective for Huntington's Disease?
Research has shown that transcranial direct current stimulation (tDCS), which participants in this trial will receive, might help people with Huntington's Disease feel better. One study found that tDCS improved memory, crucial for everyday tasks. Another study demonstrated that it enhanced movement skills, with benefits lasting up to four weeks after treatment. These findings suggest that tDCS could address the thinking and movement problems caused by Huntington’s Disease. Although more research is needed, early results offer promise for those seeking better symptom management.12456
Who Is on the Research Team?
Erin Stimming, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Are You a Good Fit for This Trial?
This trial is for individuals with Huntington's Disease in early to middle stages who show mild to moderate behavioral symptoms like apathy, irritability, or depression. They must have stable medication doses for a month and no major cognitive disorders, unstable medical conditions, brain metal objects, or high suicide risk.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive home-based transcranial direct current stimulation (tDCS) for Huntington's Disease-related symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- active tDCS
active tDCS is already approved in Canada for the following indications:
- Depression in pregnancy
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center, Houston
Lead Sponsor